Methods for Optimizing CRISPR-Cas9 Genome Editing Specificity.
about
Functional interrogation of non-coding DNA through CRISPR genome editing.GUIDEseq: a bioconductor package to analyze GUIDE-Seq datasets for CRISPR-Cas nucleases.Genome editing: progress and challenges for medical applications.Mouse Genome Informatics (MGI) Resource: Genetic, Genomic, and Biological Knowledgebase for the Laboratory Mouse.CRISPR Editing Technology in Biological and Biomedical Investigation.Advances in the delivery of RNA therapeutics: from concept to clinical reality.Applications of CRISPR genome editing technology in drug target identification and validation.Nucleosomes Selectively Inhibit Cas9 Off-target Activity at a Site Located at the Nucleosome Edge.CRISPR/Cas9-Mediated CCR5 Ablation in Human Hematopoietic Stem/Progenitor Cells Confers HIV-1 Resistance In Vivo.In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models.The Therapeutic Potential of CRISPR/Cas9 Systems in Oncogene-Addicted Cancer Types: Virally Driven Cancers as a Model System.Immunity to CRISPR Cas9 and Cas12a therapeutics.Genomes in Focus: Development and Applications of CRISPR-Cas9 Imaging Technologies.An efficient method for generation of bi-allelic null mutant mouse embryonic stem cells and its application for investigating epigenetic modifiers.Human genetic variation alters CRISPR-Cas9 on- and off-targeting specificity at therapeutically implicated loci.From Reductionism to Holism: Toward a More Complete View of Development Through Genome Engineering.The initiation, propagation and dynamics of CRISPR-SpyCas9 R-loop complex.High-Throughput Approaches to Pinpoint Function within the Noncoding Genome.Methods and Applications of CRISPR-Mediated Base Editing in Eukaryotic Genomes.Towards CRISPR/Cas crops - bringing together genomics and genome editing.CRISPR/Cas9 Gene Drive: Growing Pains for a New Technology.Marker-free coselection for CRISPR-driven genome editing in human cells.The Impact of CRISPR/Cas9 Technology on Cardiac Research: From Disease Modelling to Therapeutic Approaches.Improving CRISPR-Cas specificity with chemical modifications in single-guide RNAs.Generation of chromosomal translocations that lead to conditional fusion protein expression using CRISPR-Cas9 and homology-directed repair.Designing Epigenome Editors: Considerations of Biochemical and Locus Specificities.Genome Editing: Past, Present, and Future.Potential high-frequency off-target mutagenesis induced by CRISPR/Cas9 in Arabidopsis and its prevention.CRISPR RNA-Dependent Binding and Cleavage of Endogenous RNAs by the Campylobacter jejuni Cas9.UDiTaS™, a genome editing detection method for indels and genome rearrangements.Tackling HIV Persistence: Pharmacological versus CRISPR-Based Shock Strategies.Long Terminal Repeat CRISPR-CAR-Coupled "Universal" T Cells Mediate Potent Anti-leukemic Effects.Incorporation of bridged nucleic acids into CRISPR RNAs improves Cas9 endonuclease specificity.Receptor-Mediated Delivery of CRISPR-Cas9 Endonuclease for Cell Type Specific Gene Editing.Gene Editing and Gene-Based Therapeutics for Cardiomyopathies.Epigenetic Targeting of Granulin in Hepatoma Cells by Synthetic CRISPR dCas9 Epi-suppressors.Alpha-1 antitrypsin deficiency: outstanding questions and future directions.RNA Therapeutics in Cardiovascular Precision MedicineAll-in-one adeno-associated virus delivery and genome editing by Neisseria meningitidis Cas9 in vivoComprehensive off-target analysis of dCas9-SAM-mediated HIV reactivation via long noncoding RNA and mRNA profiling
P2860
Q36306820-9CCFFC02-3541-455A-B8D5-F5B74507CF01Q36372386-87C1F2A8-CEAA-4664-B0C4-A2644A6D7F0AQ37417137-C37636BF-8C83-4CF3-87D2-3B24558F71E2Q38371715-BA98613E-285B-4849-B5DD-5677D6DEDED4Q38688945-994874B3-3DE3-47FC-96F3-FCC8C6B3E7CDQ38706445-563F760C-3BE6-4211-B8EF-105632C50D9DQ38708498-CCACC07F-9C23-451A-A4A7-A271CC229364Q38739783-D50D9BDA-A955-4EA2-A403-2567079E37B9Q40192805-01E72018-EB56-480E-8386-90C38C2B4481Q40263108-DEB7EC5F-27ED-4EED-8A75-3B6EF30212E8Q41035560-ECA25FCC-79D0-45A5-A1B7-3B66714A8B70Q45873745-8CF1AA6E-F338-4530-B7F7-EA7BAAA67A2FQ45938620-473E9160-709D-43C2-A83F-2C5C95FF597FQ47136073-1E0F6A7E-CDD5-4C32-B3A5-4088D92A1D53Q47327388-C259DAA6-179E-485B-942A-905485361569Q47356373-8EC939C6-1F90-403E-A546-995824FA029FQ47395331-6199E3D7-90C8-4BCB-897B-4F45BD59C254Q47594697-0AB8DBB8-E736-496C-AAB5-66F8FF07829AQ47594709-FFD2F3C6-FF50-482C-A8F1-FD6F5CD11F1AQ47759481-15C7628C-89DE-4E63-B960-508590DC209BQ48153215-F1FC9E2E-ABCE-4F85-8C58-11C00D350314Q48266764-9DBD7E8E-6D4B-41A8-8F0B-08F17C22D366Q49432567-4C8EC8F5-EED3-4A62-AB8B-4BA1E0438095Q50027400-DADE33C3-930E-46E5-A527-C1A4DD7BA3A6Q50437600-18C03AB7-AD50-4AF5-A637-5F396FDE2FCAQ52360880-C510CAD0-EEEF-4263-ABA3-3A9CBC633AA0Q52429681-7931D7C5-0FA0-4C41-B817-6841ABECDE55Q52430461-9F3BF17C-5BF7-4AA3-98E8-C9C2422581DEQ52430557-A0073C36-CF11-4EA3-9D56-A800AE3C4B2EQ52430935-56D5A1CE-8301-4335-8012-C79C09942FE9Q52431127-81E6B1DB-26F6-4975-A424-B1B8B8194C53Q52431202-C96F3A4A-AA38-427F-8E9A-68444643B6D4Q52431554-03C3BC02-22DC-47D3-AD73-2A0F820476F1Q52431661-01FE9C36-659E-44AA-AE1D-D1BB8E085934Q52662536-07F059C3-3B65-4BF8-82BD-49E236D0A3E0Q55017665-D3BD9411-5EFD-4839-9D43-E6448D76C95CQ55666746-E52D3DDB-B4B8-4A0E-BFDC-FE2FBAF69ADDQ57174720-EACDE0FB-48E1-4EE7-9310-68F6E60855E8Q58324031-5F903EBA-F211-41BC-BF79-DCED65D61A6EQ58755636-6B12EB28-0AE6-4CCB-9BDC-C9B4D3540F01
P2860
Methods for Optimizing CRISPR-Cas9 Genome Editing Specificity.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Methods for Optimizing CRISPR-Cas9 Genome Editing Specificity.
@en
type
label
Methods for Optimizing CRISPR-Cas9 Genome Editing Specificity.
@en
prefLabel
Methods for Optimizing CRISPR-Cas9 Genome Editing Specificity.
@en
P2860
P1433
P1476
Methods for Optimizing CRISPR-Cas9 Genome Editing Specificity.
@en
P2093
Josh Tycko
Vic E Myer
P2860
P304
P356
10.1016/J.MOLCEL.2016.07.004
P577
2016-08-01T00:00:00Z